Clinical trial
Phase I Study of Tolerance and Pharmacokinetics of TQB2450 Injection
NCT03460457 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Tolerance and Pharmacokinetics of TQB2450 Injection
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 15, 2018
- Completion date
- March 15, 2019
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
tumor